Literature DB >> 11916543

Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

M Van Glabbeke, W Steward, J P Armand.   

Abstract

Mesh：

Year:  2002        PMID： 11916543     DOI： 10.1016/s0959-8049(01)00419-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Recommended changes to oncology clinical trial design: revolution or evolution?

Authors:  Mark J Ratain; Rachel W Humphrey; Gary B Gordon; Gwen Fyfe; Peter C Adamson; Thomas R Fleming; Walter M Stadler; Donald A Berry; Carl C Peck
Journal:  Eur J Cancer       Date:  2007-11-05       Impact factor: 9.162

2.  Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017.

Authors:  Jared C Foster; Boris Freidlin; Charles A Kunos; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

Review 3.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 4.  A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

Authors:  Michael J Grayling; Munyaradzi Dimairo; Adrian P Mander; Thomas F Jaki
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.